Scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas -- the most common and malignant of primary brain tumors -- might benefit from immunotherapy. The treatment could extend survival for an estimated 20% to 30% of patients. Currently, patients with glioblastoma do not receive this life-prolonging treatment because it has not been fully understood which of them could benefit.